Breakwater Energy Holdings S.à r.l. (the “Issuer”) today announced that it has priced an offering (the “Offering”) of $725,000,000 aggregate principal amount of its 9¼% Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from this Offering to (1) repay amounts outstanding related to the acquisition of the Issuer's ordinary […]

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your KBR, Inc. (NYSE:KBR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kbr-inc-lawsuit-submission-form?prid=175970&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your Fluor Corporation (NYSE:FLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluor-corporation-lawsuit-submission-form?prid=175971&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

(NASDAQ:ELDN), Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m(2) Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into Phase 3 development as

(NASDAQ:AKBA), CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the presentation of a post-hoc win odds analysis of all-cause mortality and hospitalization from the Phase 3 INNO2VATE trials of vadadustat at the

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting GlobeNewswire November 06, 2025 Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of

Vafseo(R) (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 GlobeNewswire November 06, 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA), a biopharmaceutical

A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg The new class action, King v. aTyr Pharma Inc., filed in the U.S. District Court for the Southern District of California on

(NasdaqGM:ALVO), NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Alvotech (the “Company”) (NASDAQ: ALVO) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO) GlobeNewswire November 06, 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Alvotech (the “Company”) (NASDAQ: ALVO) or certain of its officers and directors issued